- |||||||||| 2-fluorofucose (SGN-2FF) / Pfizer
Trial termination, PD(L)-1 Biomarker, Metastases: A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 18, 2019 P1, N=47, Terminated, The agent shows pre-clinical efficacy for both cancer treatment and prevention. Active, not recruiting --> Terminated; Due to overall benefit/risk profile
- |||||||||| 2-fluorofucose (SGN-2FF) / Pfizer
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 10, 2019 P1, N=47, Active, not recruiting, Active, not recruiting --> Terminated; Due to overall benefit/risk profile Recruiting --> Active, not recruiting | N=308 --> 47 | Trial completion date: Aug 2022 --> Jun 2019 | Trial primary completion date: Dec 2019 --> Jun 2019
- |||||||||| 2-fluorofucose (SGN-2FF) / Pfizer
Enrollment change, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 12, 2018 P1, N=308, Recruiting, Recruiting --> Active, not recruiting | N=308 --> 47 | Trial completion date: Aug 2022 --> Jun 2019 | Trial primary completion date: Dec 2019 --> Jun 2019 N=158 --> 308 | Trial completion date: May 2022 --> Aug 2022 | Trial primary completion date: Jul 2019 --> Dec 2019
- |||||||||| 2-fluorofucose (SGN-2FF) / Pfizer
Enrollment open, Trial primary completion date, PD(L)-1 Biomarker, Metastases: A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 29, 2017 P1, N=158, Recruiting, N=158 --> 308 | Trial completion date: May 2022 --> Aug 2022 | Trial primary completion date: Jul 2019 --> Dec 2019 Not yet recruiting --> Recruiting | Trial primary completion date: May 2018 --> Jul 2019
|